Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
暂无分享,去创建一个
C. Cannon | R. Pratley | S. Dagogo-Jack | R. Frederich | Jie Liu | I. Gantz | D. Cherney | Harry Shi | U. Masiukiewicz | F. Cosentino
[1] C. Cannon,et al. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin , 2022, Diabetes, obesity & metabolism.
[2] M. Barbieri,et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials , 2022, Frontiers in Cardiovascular Medicine.
[3] E. Huang,et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.
[4] B. Zinman,et al. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial , 2021, Diabetes, obesity & metabolism.
[5] A. Janež,et al. SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review , 2021, Diabetes Therapy.
[6] C. Cannon,et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.
[7] A. Scheen. Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus , 2020, Nature Reviews Endocrinology.
[8] X. Qu,et al. Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes , 2020, Frontiers in Endocrinology.
[9] K. Mahaffey,et al. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program , 2020, Diabetes, obesity & metabolism.
[10] H. Ishihara,et al. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy , 2019, Clinical Drug Investigation.
[11] K. Kostev,et al. Time to Insulin Initiation in Type 2 Diabetes Patients in 2010/2011 and 2016/2017 in Germany , 2019, Journal of diabetes science and technology.
[12] C. Cannon,et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.
[13] Merlin C Thomas,et al. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure , 2018, Diabetologia.
[14] K. Khunti,et al. Identification of barriers to insulin therapy and approaches to overcoming them , 2017, Diabetes, obesity & metabolism.
[15] K. Tziomalos. Barriers to insulin treatment in patients with type 2 diabetes mellitus , 2017, Expert opinion on pharmacotherapy.
[16] R. DeFronzo,et al. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.
[17] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[18] F. Gueyffier,et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials , 2016, BMC Endocrine Disorders.
[19] J. Rosenstock,et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.
[20] K. Mahaffey,et al. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes , 2014, Diabetes Care.
[21] J. Rosenstock,et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.
[22] V. Woo,et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years , 2014, Diabetes, obesity & metabolism.
[23] V. Woo,et al. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin , 2012, Annals of Internal Medicine.
[24] E. Ferrannini,et al. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects , 2012, Nature Reviews Endocrinology.
[25] D. Nathan,et al. Measuring Psychological Insulin Resistance , 2008, The Diabetes educator.
[26] S. Vinker,et al. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. , 2007, Journal of diabetes and its complications.
[27] R. Rubin,et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. , 2005, Diabetes care.
[28] M Nurminen,et al. Comparative analysis of two rates. , 1985, Statistics in medicine.